|Jmol-3D images||Image 1|
|Molar mass||351.42 g/mol|
| (what is: / ?) |
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
LY-334,370 is a selective 5-HT1F receptor agonist which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals.
- Lasmiditan, another 5-HT1F agonist for the treatment of migraine
- Medical Subject Headings (MeSH)
|This drug article relating to the nervous system is a stub. You can help World Heritage Encyclopedia by expanding it.|